Page last updated: 2024-11-12

madangamine a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

madangamine A: from sponge Xestospongia ingens; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9980274
CHEMBL ID4786764
MeSH IDM0495635

Synonyms (4)

Synonym
madangamine a
155944-26-6
DTXSID701015847
CHEMBL4786764

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Treatment with madangamine A increased the levels of LC3-II and p62, autophagy-related proteins, concomitant with growth inhibition."( Identification of madangamine A as a novel lysosomotropic agent to inhibit autophagy.
Chida, N; Kawano, S; Miura, K; Sato, T; Simizu, S; Suto, T, 2021
)
1.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1719514Induction of autophagosome formation in human HeLa cells assessed as increase in LC3 puncta at 10 uM after 24 hrs in presence of Baf A1 by Alexa Fluor 488 staining based fluorescence microscopic analysis2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Identification of madangamine A as a novel lysosomotropic agent to inhibit autophagy.
AID1719519Modulation of autophagy in human HeLa cells assessed as increase in LC3-2 protein level at 10 uM after 24 hrs in presence of chloroquine by Western blot analysis2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Identification of madangamine A as a novel lysosomotropic agent to inhibit autophagy.
AID1719524Inhibition of autophagy in human HeLa cells assessed as decrease in cathepsin B at 10 nM after 24 hrs by immunoblot analysis2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Identification of madangamine A as a novel lysosomotropic agent to inhibit autophagy.
AID1719516Induction of autophagosome formation in HT-1080 cells assessed as increase in LC3 puncta at 10 uM after 24 hrs by Alexa Fluor 488 staining based fluorescence microscopic analysis2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Identification of madangamine A as a novel lysosomotropic agent to inhibit autophagy.
AID1719515Induction of autophagosome formation in human HeLa cells assessed as increase in LC3 puncta at 10 uM after 6 hrs in presence of rapamycin by Alexa Fluor 488 staining based fluorescence microscopic analysis2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Identification of madangamine A as a novel lysosomotropic agent to inhibit autophagy.
AID1719512Induction of autophagosome formation in human HeLa cells assessed as increase in LC3 puncta at 10 uM after 24 hrs by Alexa Fluor 488 staining based fluorescence microscopic analysis2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Identification of madangamine A as a novel lysosomotropic agent to inhibit autophagy.
AID1719522Inhibition of autophagy in human HeLa cells assessed as increase in lysosomal pH at 10 uM after 24 hrs by LysoTracker Red DND-99 staining based fluorescence microscopic method2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Identification of madangamine A as a novel lysosomotropic agent to inhibit autophagy.
AID1719517Induction of autophagosome formation in SK-MEL-28 cells assessed as increase in LC3 puncta at 10 uM after 24 hrs by Alexa Fluor 488 staining based fluorescence microscopic analysis2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Identification of madangamine A as a novel lysosomotropic agent to inhibit autophagy.
AID1719507Antiproliferative activity against human HeLa cells assessed as cell viability at 1 uM after 24 hrs by MTT assay relative to control2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Identification of madangamine A as a novel lysosomotropic agent to inhibit autophagy.
AID1719508Modulation of autophagy in human HeLa cells assessed as increase in LC3-2 protein level at 1 to 20 uM after 24 hrs by Western blot analysis2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Identification of madangamine A as a novel lysosomotropic agent to inhibit autophagy.
AID1719509Inhibition of autophagy in human HeLa cells assessed as increase in P62 protein level at 1 to 20 uM after 24 hrs by Western blot analysis2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Identification of madangamine A as a novel lysosomotropic agent to inhibit autophagy.
AID1719510Antiproliferative activity against human HeLa cells assessed as cell viability at 20 uM after 24 hrs by MTT assay relative to control2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Identification of madangamine A as a novel lysosomotropic agent to inhibit autophagy.
AID1719520Inhibition of autophagy in human HeLa cells assessed as increase in P62 protein level at 10 uM after 24 hrs in presence of Baf A1 by Western blot analysis2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Identification of madangamine A as a novel lysosomotropic agent to inhibit autophagy.
AID1719518Modulation of autophagy in human HeLa cells assessed as increase in LC3-2 protein level at 10 uM after 24 hrs in presence of Baf A1 by Western blot analysis2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Identification of madangamine A as a novel lysosomotropic agent to inhibit autophagy.
AID1719511Antiproliferative activity against human HeLa cells assessed as cell viability at 10 uM after 24 hrs by MTT assay relative to control2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Identification of madangamine A as a novel lysosomotropic agent to inhibit autophagy.
AID1719521Inhibition of autophagy in human HeLa cells assessed as increase in P62 protein level at 10 uM after 24 hrs in presence of chloroquine by Western blot analysis2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Identification of madangamine A as a novel lysosomotropic agent to inhibit autophagy.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's2 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.78 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]